Bypass Surgery Shows Long-Term Survival Advantage Over Stenting
This article was originally published in The Gray Sheet
Executive Summary
Drug-eluting stent manufacturers with an eye toward multi-vessel and diabetic-specific indications face a new hurdle in the recent release of observational data pointing to lower mortality among patients receiving bypass surgery compared with stenting
You may also be interested in...
Boston Scientific To Study Complex DES Use; Taxus Complaints Surface
Boston Scientific is maintaining a "sober" outlook regarding its chances of obtaining increased reimbursement in the near-term for multi-vessel interventions using drug-eluting stents
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.